Literature DB >> 27559075

Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Véronique Avettand-Fènoël1, Laurent Hocqueloux2, Jade Ghosn3, Antoine Cheret4, Pierre Frange5, Adeline Melard6, Jean-Paul Viard3, Christine Rouzioux7.   

Abstract

HIV-1 DNA persists in infected cells despite combined antiretroviral therapy (cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs have rekindled hopes of curing HIV infection, and reliable markers are thus needed to evaluate viral reservoirs. Total HIV DNA quantification is simple, standardized, sensitive, and reproducible. Total HIV DNA load influences the course of the infection and is therefore clinically relevant. In particular, it is predictive of progression to AIDS and death, independently of HIV RNA load and the CD4 cell count. Baseline total HIV DNA load is predictive of the response to cART. It declines during cART but remains quantifiable, at a level that reflects both the history of infection (HIV RNA zenith, CD4 cell count nadir) and treatment efficacy (residual viremia, cumulative viremia, immune restoration, immune cell activation). Total HIV DNA load in blood is also predictive of the presence and severity of some HIV-1-associated end-organ disorders. It can be useful to guide individual treatment, notably, therapeutic de-escalation. Although it does not distinguish between replication-competent and -defective latent viruses, the total HIV DNA load in blood, tissues, and cells provides insights into HIV pathogenesis, probably because all viral forms participate in host cell activation and HIV pathogenesis. Total HIV DNA is thus a biomarker of HIV reservoirs, which can be defined as all infected cells and tissues containing all forms of HIV persistence that participate in pathogenesis. This participation may occur through the production of new virions, creating new cycles of infection and disseminating infected cells; maintenance or amplification of reservoirs by homeostatic cell proliferation; and viral transcription and synthesis of viral proteins without new virion production. These proteins can induce immune activation, thus participating in the vicious circle of HIV pathogenesis.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27559075      PMCID: PMC5010749          DOI: 10.1128/CMR.00015-16

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  266 in total

1.  Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men.

Authors:  T M Lampinen; C W Critchlow; J M Kuypers; C S Hurt; P J Nelson; S E Hawes; R W Coombs; K K Holmes; N B Kiviat
Journal:  AIDS       Date:  2000-03-31       Impact factor: 4.177

2.  Can we avoid treatment interruption studies in the search for an HIV cure?

Authors:  Jade Ghosn; Constance Delaugerre
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

3.  Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.

Authors:  Francesca Vitone; Davide Gibellini; Pasqua Schiavone; Maria Carla Re
Journal:  J Clin Virol       Date:  2004-12-15       Impact factor: 3.168

4.  Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection.

Authors:  F Clayton; G Snow; S Reka; D P Kotler
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

5.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

Review 6.  The mucosal immune system: primary target for HIV infection and AIDS.

Authors:  R S Veazey; P A Marx; A A Lackner
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

7.  Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution.

Authors:  A C Karlsson; M Birk; S Lindbäck; H Gaines; J E Mittler; A Sönnerborg
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

8.  HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults.

Authors:  Albert K Minga; Xavier Anglaret; Thomas d' Aquin Toni; Marie-Laure Chaix; Lambert Dohoun; Yao Abo; Ali Coulibaly; Julien Duvignac; Delphine Gabillard; François Rouet; Christine Rouzioux
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Human macrophages support persistent transcription from unintegrated HIV-1 DNA.

Authors:  Jeremy Kelly; Margaret H Beddall; Dongyang Yu; Subashini R Iyer; Jon W Marsh; Yuntao Wu
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

View more
  70 in total

1.  New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.

Authors:  Mélanie Bertine; Marie Gueudin; Adeline Mélard; Florence Damond; Diane Descamps; Sophie Matheron; Fidéline Collin; Christine Rouzioux; Jean-Christophe Plantier; Véronique Avettand-Fenoel
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

Review 2.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

3.  Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR.

Authors:  Steven M Lada; Karissa Huang; D Jake VanBelzen; Luis J Montaner; Una O'Doherty; Douglas D Richman
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

Review 4.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

5.  Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.

Authors:  Lesley R de Armas; Suresh Pallikkuth; Stefano Rinaldi; Rajendra Pahwa; Savita Pahwa
Journal:  AIDS Res Hum Retroviruses       Date:  2019 Nov/Dec       Impact factor: 2.205

6.  Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Dolores Vaira; Michel Moutschen; Gilles Darcis; Nathalie Maes; Alexander O Pasternak; Anne-Sophie Sauvage; Frédéric Frippiat; Christelle Meuris; Françoise Uurlings; Marianne Lecomte; Philippe Léonard; Majdouline Elmoussaoui; Karine Fombellida
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Novel Transmitted/Founder Simian-Human Immunodeficiency Viruses for Human Immunodeficiency Virus Latency and Cure Research.

Authors:  Anya M Bauer; Widade Ziani; Emily Lindemuth; Leticia Kuri-Cervantes; Hui Li; Fang-Hua Lee; Meagan Watkins; Wenge Ding; Huanbin Xu; Ronald Veazey; Katharine J Bar
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

8.  Psychosocial Correlates of Monocyte Activation and HIV Persistence in Methamphetamine Users.

Authors:  Kaitlin Grosgebauer; Jessica Salinas; Mark Sharkey; Margaret Roach; Suresh Pallikkuth; Samantha E Dilworth; Savita Pahwa; Tulay Koru-Sengul; Mario Stevenson; Adam W Carrico
Journal:  J Neuroimmune Pharmacol       Date:  2018-07-25       Impact factor: 4.147

9.  Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response.

Authors:  Guoxin Wu; Paul Zuck; Shih Lin Goh; Jeffrey M Milush; Poonam Vohra; Joseph K Wong; Ma Somsouk; Steven A Yukl; Barbara L Shacklett; Nicolas Chomont; Ashley T Haase; Hiroyu Hatano; Timothy W Schacker; Steven G Deeks; Daria J Hazuda; Peter W Hunt; Bonnie J Howell
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

10.  Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.

Authors:  Widade Ziani; Anya Bauer; Hong Lu; Xiaolei Wang; Xueling Wu; Katharine J Bar; Hui Li; Dongfang Liu; George M Shaw; Ronald S Veazey; Huanbin Xu
Journal:  J Virol       Date:  2021-04-12       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.